Elicio Therapeutics Q2 FY26 net loss narrows to $8.2 million; loss per share improves to $0.43

Reuters2026/08/13 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Second-quarter net loss narrowed to USD 8.2 million; loss per share improved to USD 0.43.
R&D expense dipped to USD 6.8 million on lower clinical trial costs; G&A expense climbed to USD 3.6 million.
Cash and cash equivalents totaled USD 23.5 million as of June 30, 2026; July financing raised USD 15 million gross.
Cash runway expected into Q1 2027; Phase 1 ELI-002 7P combination study in metastatic pancreatic cancer targeted for Q4 2026 start.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809242) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elicio Therapeutics Q2 FY26 net loss narrows to $8.2 million; loss per share improves to $0.43

You may also like

Crypto prices